Krystal Biotech Inc (KRYS)
170.85
-5.54
(-3.14%)
USD |
NASDAQ |
Nov 04, 16:00
171.06
+0.21
(+0.12%)
After-Hours: 20:00
Krystal Biotech Enterprise Value: 4.508B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 4.508B |
| October 31, 2024 | 4.397B |
| October 30, 2024 | 4.483B |
| October 29, 2024 | 4.503B |
| October 28, 2024 | 4.522B |
| October 25, 2024 | 4.483B |
| October 24, 2024 | 4.467B |
| October 23, 2024 | 4.403B |
| October 22, 2024 | 4.474B |
| October 21, 2024 | 4.582B |
| October 18, 2024 | 4.589B |
| October 17, 2024 | 4.520B |
| October 16, 2024 | 4.548B |
| October 15, 2024 | 4.568B |
| October 14, 2024 | 4.600B |
| October 11, 2024 | 4.575B |
| October 10, 2024 | 4.415B |
| October 09, 2024 | 4.381B |
| October 08, 2024 | 4.464B |
| October 07, 2024 | 4.468B |
| October 04, 2024 | 4.529B |
| October 03, 2024 | 4.495B |
| October 02, 2024 | 4.537B |
| October 01, 2024 | 4.654B |
| September 30, 2024 | 4.670B |
| Date | Value |
|---|---|
| September 27, 2024 | 4.530B |
| September 26, 2024 | 4.566B |
| September 25, 2024 | 4.598B |
| September 24, 2024 | 4.597B |
| September 23, 2024 | 4.617B |
| September 20, 2024 | 4.732B |
| September 19, 2024 | 4.740B |
| September 18, 2024 | 4.691B |
| September 17, 2024 | 4.878B |
| September 16, 2024 | 5.022B |
| September 13, 2024 | 5.232B |
| September 12, 2024 | 5.061B |
| September 11, 2024 | 5.152B |
| September 10, 2024 | 4.755B |
| September 09, 2024 | 4.833B |
| September 06, 2024 | 4.732B |
| September 05, 2024 | 4.786B |
| September 04, 2024 | 4.783B |
| September 03, 2024 | 4.807B |
| August 30, 2024 | 5.046B |
| August 29, 2024 | 5.049B |
| August 28, 2024 | 5.299B |
| August 27, 2024 | 5.135B |
| August 26, 2024 | 5.201B |
| August 23, 2024 | 5.232B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
414.19M
Minimum
Mar 18 2020
5.574B
Maximum
Jul 26 2024
1.836B
Average
1.354B
Median
Aug 30 2022
Enterprise Value Benchmarks
| Bioventus Inc | 1.273B |
| ADMA Biologics Inc | 4.558B |
| Axsome Therapeutics Inc | 4.128B |
| Amicus Therapeutics Inc | 3.531B |
| Sarepta Therapeutics Inc | 11.52B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 15.57M |
| Revenue (Quarterly) | 70.28M |
| Total Expenses (Quarterly) | 49.22M |
| EPS Diluted (Quarterly) | 0.53 |
| Gross Profit Margin (Quarterly) | 91.45% |
| Profit Margin (Quarterly) | 22.15% |
| Earnings Yield | 2.14% |
| Operating Earnings Yield | 0.08% |
| Normalized Earnings Yield | 0.9774 |